High rate of complete remission and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant in patients with multiple myeloma. Results of a phase II prospective study

被引：0
|
作者：
Sahebi, F. [1 ]
Krishnan, A. [1 ]
Farol, L. [1 ]
Cai, J. -L. [1 ]
Somlo, G. [1 ]
Popplewell, L. [1 ]
Parker, P. [1 ]
Spielberger, R. [1 ]
Kogut, N. [1 ]
Karanes, C. [1 ]
Ruel, C. [1 ]
Frankel, P. [1 ]
Reburiano, E. [1 ]
Duarte, L. [1 ]
O'Donnell, L. [1 ]
Forman, S. [1 ]
机构：
[1] City Hope Med Ctr, Duarte, CA USA
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [41] Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Buda, Gabriele
    Fazzi, Rita
    Carulli, Giovanni
    Galimberti, Sara
    Sammuri, Paola
    Orciuolo, Enrico
    Petrini, Iacopo
    Accardi, Fabrizio
    Notarfranchi, Laura
    Giuliani, Nicola
    Petrini, Mario
    BLOOD, 2016, 128 (22)
  • [42] Phase II trial of GM-CSF as maintenance therapy post-autologous peripheral blood stem cell transplantation in multiple myeloma
    Mandanas, RA
    Beveridge, R
    Rifkin, RM
    Greenspan, AR
    Orloff, GJ
    Klein, LM
    Rauch, MA
    Boehm, KA
    Zhan, F
    Asmar, L
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 75 - 75
  • [43] Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant
    Vij, Ravi
    Ansstas, George
    Mosley, James C.
    Bryant, George
    Hassan, Anjum
    Amador-Ortiz, Catalina
    Procknow, Elizabeth
    LEUKEMIA & LYMPHOMA, 2010, 51 (08) : 1577 - 1579
  • [44] COMBINATION OF IFN-/GM-CSF AS MAINTENANCE THERAPY FOR MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS OF A PROSPECTIVE PHASE II STUDY
    Salmasinia, D.
    Moreb, J. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 68 - 68
  • [45] Response post first autologous stem cell transplantation (ASCT) for multiple myeloma identify patients who may benefit from tandem transplants: A single center prospective phase II study
    Moreb, Jan S.
    Salmasinia, Donya
    Leather, Helen
    Davis, Amy
    Hsu, Jack
    Wiggins, Laura
    Cogle, Christopher R.
    Chang, Myron N.
    Wingard, John R.
    CANCER RESEARCH, 2012, 72
  • [46] Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
    Harousseau, Jean-Luc
    Attal, Michel
    Leleu, Xavier
    Troncy, Jacques
    Pegourie, Brigitte
    Stoppa, Anne-Marie
    Hulin, Cyrille
    Benboubker, Lofti
    Fuzibet, Jean-Gabriel
    Renaud, Marc
    Moreau, Philippe
    Avet-Loiseau, Herve
    HAEMATOLOGICA, 2006, 91 (11) : 1498 - 1505
  • [47] Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission
    Cohen, Adam D.
    Garfall, Alfred L.
    Susanibar-Adaniya, Sandra Patricia
    Vogl, Dan T.
    Waxman, Adam
    De Mesa, Oksana
    Kane, Elizabeth
    Nichols, Charles
    Razzo, Beatrice
    Stadtmauer, Edward A.
    BLOOD, 2022, 140 : 12628 - 12629
  • [48] Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response.
    Rifkin, Robert M.
    Spitzer, Gary
    Greenspan, Andrew
    Schwerkoske, John F.
    Mandanas, Romeo A.
    Stephenson, Joe
    Kannarkat, George T.
    Zhan, Feng
    Asmar, Lina
    Beveridge, Roy
    BLOOD, 2008, 112 (11) : 960 - 960
  • [49] Bortezomib (BTZ) prior to and as maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM): Long-term follow-up of a phase II study
    Goyal, S. D.
    Uy, G.
    DiPersio, J. F.
    Vij, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] A Prospective, Multicenter Phase II Study of Consolidation with Cyclophosphamide, Bortezomib and Dexamethasone (CVD) in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation; The KMM130 Study
    Eom, Hyeon-Seok
    Jung, Jongheon
    Kim, Kihyun
    Min, Chang Ki
    Lee, Je-Jung
    Yoon, Sung-Soo
    Lee, Jae Hoon
    Kim, Jin Seok
    Shin, Ho-Jin
    Bang, Soo-Mee
    Sohn, Sang Kyun
    Suh, Cheolwon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E291 - E291
12345